GlobeNewsWire
30 Apr 2026, 20:01 UTC · 26w ago
Impact · against what's priced in
Syndax (SNDX) shows strong commercial momentum with a 224% revenue increase and narrowing losses, while providing clear timelines for near-term clinical catalysts in 2Q26 and 4Q26. Incyte (INCY) benefits from the continued uptake of Niktimvo, which generated $55.1 million in net revenue for the quarter.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
Syndax reported a 224% year-over-year increase in total first quarter 2026 revenue to $64.9 million.
More positive than 92% of claims this week
Topline data for axatilimab (Niktimvo) in Phase 2 trials for IPF and newly diagnosed chronic GVHD is expected in 4Q26.
So whatPositive results in these indications would significantly expand the addressable market and valuation of the drug.
Continue reading
5 related stories
The company reported a massive 224% year-over-year revenue increase to $64.9 million and highlighted that nearly half of KMT2A patients are receiving stem cell transplants via Revuforj, supporting long-term growth.
Read from the article alone
No priced-in read yet
Niktimvo generated $55.1 million in net revenue for the first quarter of 2026, confirming strong demand for the drug in the current commercial phase.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 84% of claims this week
New real-world, frontline, and post-HSCT maintenance data for revumenib (Revuforj) is anticipated in 2Q26.
More positive than 75% of claims this week
The company reported a reduced net loss of $42.7 million for 1Q26 compared to $84.8 million in the prior year period.
More positive than 60% of claims this week
Syndax maintains a cash position of $352.1 million as of March 31, 2026.
So whatProvides a necessary liquidity cushion to fund ongoing pivotal trials and operations without immediate dilution.
More positive than 47% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
24m ago
−33.3%
Price is moving against the score
$14.29 vs $21.43 close before publication (Apr 30) · not market-adjusted
SNDX chart →+23.4%
Price agrees with the score
$117.59 vs $95.27 close before publication (Apr 30) · not market-adjusted
INCY chart →
